Cyclerion Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Thank you all for coming. I'm Peter Hecht. I'm the CEO of Cyclerion. It's great to have you all here this morning. And it's really a great pleasure to debut our company. We're a brand-new startup in Kendall Square. We're 9 months old. And we're -- I think, a really interesting investment opportunity. I think to -- right at this point, is an entry point for investors to capture tremendous upside value and a company that has a leadership team that's proven that they can create medicines and create value for shareholders.
We have a portfolio of starting assets that were developed by a team that has expertise in the category. We're focused on around the nitric oxide and cyclic GMP pathway. World experts, from Mark Currie, our President and the innovator around many of these molecules and Andy Busch, who's our head of R&D, who has a very long track record in multiple companies around this mechanism. Mike Mendelsohn, who is on our board and has been working in this category for a long time. And a terrific R&D team who have
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |